Leerink Swann's Paul Matteis reiterated his Buy to
Post# of 83
Posted On: 01/22/2016 10:26:40 AM
Re: Lucky Jimmy #67
Leerink Swann's Paul Matteis reiterated his Buy today on $NBIX Neurocrine Biosciences with a target price of $76 dollars.
"Leerink analyst Paul Matteis says he's more bullish on Neurocrine Biosciences after performing an analysis on the company's NBI-98854 in Tourette's Syndrome. The analyst believes little is priced into Neurocrine shares for Tourette's. He estimates the peak opportunity at $600M for the company. Matteis raised his price target for the shares to $76 and $71 and reiterates an Outperform rating on Neurocrine."
http://thefly.com/landingPageNews.php?id=2315...s-analysis
"Leerink analyst Paul Matteis says he's more bullish on Neurocrine Biosciences after performing an analysis on the company's NBI-98854 in Tourette's Syndrome. The analyst believes little is priced into Neurocrine shares for Tourette's. He estimates the peak opportunity at $600M for the company. Matteis raised his price target for the shares to $76 and $71 and reiterates an Outperform rating on Neurocrine."
http://thefly.com/landingPageNews.php?id=2315...s-analysis
(0)
(0)